Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors

References

1. • Björnsson E.S.
   • Hoofnagle J.H.
   Categorization of drugs implicated in causing liver injury: critical assessment based upon published case reports.
   Hepatology. 2016; 63: 590-603. 2
   View in Article

   • Google Scholar
2. • U.S. Food and Drug Administration
   Drug induced liver injury rank (DILIRank) dataset.
   (Available at:)
   https://www.fda.gov/science-resea rch/liver-toxicity-knowledge-base-ltkb/drug-induced-liverinjury-rank-dilirank-dataset
   (Accessed October 2022)
   View in Article

   • Google Scholar
3. • Hoofnagle J.H.
   • Bjornsson E.S.
   Drug induced liver injury: types and phenotypes.
   N Engl J Med. 2019; 381: 264-273
   View in Article

   • Google Scholar
4. • Shah P.
   • Sundaram V.
   • Bjornsson E.S.
   Biologic and checkpoint inhibitor-induced liver injury: a systematic literature review.
   Hepatol Commun. 2020; 4: 172-184
   View in Article

   • Google Scholar
5. • Hernandez N.
   • Bessone F.
   Hepatotoxicity induced by biological agents: clinical features and current controversies.
   J Clin Transpational Hepatol. 2022; 10: 486-495
   View in Article

   • Google Scholar
6. • Bruno Christopher
   • Fremd Brandon
   • Church Rachel
   • et al.
   HLA Associations with Infliximab-Induced Liver Injury.
   Pharmacogenomics J. 2020; 5: 681-686
   View in Article

   • Google Scholar
7. • Björnsson H.K.
   • Gudbjörnsson B.
   • Björnsson E.S.
   Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment.
   J Hepatol J Hepatol. 2022; 76: 86-92
   View in Article

   • Google Scholar
8. • Björnsson E.S.
   • Gunnarsson B.I.
   • Gröndal G.
   • et al.
   The risk of drug-induced liver injury from Tumor Necrosis Factor (TNF)-alpha-antagonists.
   Clin Gastroenterol Hepatol. 2015; 13: 602-608
   View in Article

   • Google Scholar
9. • Meunier L.
   • Malezieux E.
   • Bozon A.
   • et al.
   Can azathioprine prevent infliximab-induced liver injury?.
   J Hepatol. 2022; (S0168- 8278(22)00124-00126)
   View in Article

   • Google Scholar
10. • Strik A.S.
    • van Den Brink G.R.
    • Ponsioen C.
    • et al.
    Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017; 45: 1128-1134
    View in Article

    • Google Scholar
11. • Bjornsson E.S.
    • Bergmann O.M.
    • Bjornsson H.K.
    • et al.
    Incidence, Presentation and Outcomes in Patients with Drug-Induced Liver Injury in the General Population of Iceland.
    Gastroenterology. 2013; 144: 1419-1425
    View in Article

    • Google Scholar
12. • Shelton E.
    • Chaudrey K.
    • Sauk J.
    • et al.
    New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2015; 41: 972-979
    View in Article

    • Google Scholar
13. • Koller T.
    • Galambosova M.
    • Filakovska S.
    • et al.
    Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study.
    World J Gastroenterol. 2017; 23: 4102-4111
    View in Article

    • Google Scholar
14. • Worland T.
    • Chin K.L.
    • van Langenberg D.
    • et al.
    Retrospective study of idiosyncratic drug-induced liver injury from infliximab in an inflammatory bowel disease cohort: the IDLE study.
    Ann Gastroenterol. 2020; 33: 162-169
    View in Article

    • Google Scholar
15. • Ghabril M.
    • Bonkovsky H.L.
    • Kum C.
    • et al.
    Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases.
    Clin Gastroenterol Hepatol. 2013; 11: 558-564
    View in Article

    • Google Scholar
16. • Rodrigues S.
    • Lopes S.
    • Magro F.
    • et al.
    Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases.
    World J Gastroenterol. 2015; 21: 7584
    View in Article

    • Google Scholar
17. • Björnsson E.S.
    • Medina-Caliz I.
    • Andrade R.J.
    • et al.
    Setting Up Criteria Hepatol Commun. 2022; 6: 1895-1909
    View in Article

    • Google Scholar
18. • Harada K.
    • Akai Y.
    • Koyama S.
    • et al.
    A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis.
    Clin Rheumatol. 2008; 27: 1063-1066
    View in Article

    • Google Scholar
19. • Fathalla B.M.
    • Goldsmith D.P.
    • Pascasio
    • et al.
    Development of autoimmune hepatitis in a child with systemic-onset juvenile idiopathic arthritis during therapy with etanercept.
    J Clin Rheumat. 2008; 14: 297-298
    View in Article

    • Google Scholar
20. • Bjornsson E.
    • Talwalkar J.
    • Treeprasertsuk S.
    • et al.
    Patients with typical laboratory features of Autoimmune Hepatitis rarely need a liver biopsy for diagnosis.
    Clin Gastroenterol Hepatol. 2010; 9: 57-63
    View in Article

    • Google Scholar
21. • Lerhardi E.
    • Valle N.D.
    • Nacchiero M.C.
    • et al.
    Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis.
    Clin Drug Investig. 2006; 26: 673-676
    View in Article

    • Google Scholar
22. • Menghini V.V.
    • Arora A.S.
    Infliximab-associated reversible cholestatic liver disease.
    Mayo Clin Proc. 2001; 76: 84-86
    View in Article

    • Google Scholar
23. • Michel M.
    • Duvoux C.
    • Hezode C.
    • et al.
    Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still’s disease.
    J Rheumatol. 2003; 30: 1624-1625
    View in Article

    • Google Scholar
24. • Ostuni P.
    • Botsios C.
    • Punzi L.
    • et al.
    Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.
    Ann Rheum Dis. 2003; 62: 686-687
    View in Article

    • Google Scholar
25. • Esteve M.
    • Saro C.
    • González-Huix F.
    • et al.
    Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis.
    Gut. 2004; 53: 1363-1365
    View in Article

    • Google Scholar
26. • Reddy K.R.
    • Beavers K.L.
    • Hammond S.P.
    • et al.
    American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunsuppressive drug therapy.
    Gastroenterology. 2015; 148: 215-219
    View in Article

    • Google Scholar
27. • Tobon G.J.
    • Canas C.
    • Jaller J.J.
    • et al.
    Serious liver disease induced by infliximab.
    Clin Rheumatol. 2007; 26: 578-581
    View in Article

    • Google Scholar
28. • Kinnunen U.
    • Färkkilä M.
    • Mäkisalo H.
    A case report: ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis.
    J Crohns Colitis. 2012; 6: 724-727
    View in Article

    • Google Scholar
29. • Haennig A.
    • Bonnet D.
    • Thebault S.
    • et al.
    Infliximab induced acute hepatitis during Crohn’s disease therapy: absence of cross-toxicity with adalimumab.
    Gastroenterol Clin Biol. 2010; 34: e7-e8. 29
    View in Article

    • Google Scholar
30. • Caussé S.
    • Bouquin R.
    • Wylomanski S.
    • et al.
    Infliximab-induced hepatitis during treatment of vulvar Crohn’s disease [in French].
    Ann Dermatol Venereol. 2013; 140: 46-51
    View in Article

    • Google Scholar
31. • Parra R.S.
    • Feitosa M.R.
    • Machado V.F.
    • et al.
    Infliximab-associated fulminant hepatic failure in ulcerative colitis: a case report.
    J Med Case Rep. 2015; 9: 249
    View in Article

    • Google Scholar
32. • Forker R.
    • Escher M.
    • Stange E.F.
    A 20-year-old woman with ulcerative colitis and acute liver failure.
    Internist (Berl). 2017; 58: 982-989
    View in Article

    • Google Scholar
33. • Kok B.
    • Lester E.L.W.
    • Lee W.M.
    • et al.
    United States Acute Liver Failure Study Group. Acute liver failure from tumor necrosis factor-a antagonists: report of four cases and literature review.
    Dig Dis Sci. 2018; 63: 1654-1666
    View in Article

    • Google Scholar
34. • Wong F.
    • Ibrahim B.A.
    • Walsh J.
    • et al.
    Infliximab-induced autoim- mune hepatitis requiring liver transplanEiswerthtation.
    Clin Case Rep. 2019; 7: 2135-2139
    View in Article

    • Google Scholar
35. • Mustafa Alikhan M.
    • Mansoor E.
    • Satyavada S.
    • et al.
    Infliximab-induced acute liver failure in a patient with crohn's disease requiring orthotopic liver transplantation.
    ACG Case Rep J. 2021; 8: e00586
    View in Article

    • Google Scholar
36. • Bonkovsky H.L.
    • Kleiner D.
    • Gu J.
    • et al.
    Clinical presentation and outcomes of bile duct loss caused by drugs and dietary supplements.
    Hepatology. 2017; 65: 1267-1277
    View in Article

    • Google Scholar
37. • Shah P.
    • Larson B.
    • Wishingrad M.
    • et al.
    Now You See It, Now You Don’t: a case report of Infliximab-induced vanishing bile duct syndrome.
    ACG Case Rep. 2019; 6: e00134
    View in Article

    • Google Scholar
38. • Eiswerth M.J.
    • Heckroth M.A.
    • Ismail A.
    • et al.
    Infliximab-induced vanishing bile duct syndrome.
    Cureus. 2022; 14: e21940
    View in Article

    • Google Scholar
39. • Pennock G.K.
    • Chow L.Q.
    The evolving role of immune checkpoint inhibitors in cancer treatment.
    Oncologist. 2015; 20: 812-822
    View in Article

    • Google Scholar
40. • Malnick S.D.H.
    • Abdullah A.
    • Neuman M.G.
    Checkpoint inhibitors and hepatotoxicity.
    Biomedicines. 2021; 9: 101
    View in Article

    • Google Scholar
41. • Tawbi H.A.
    • Schadendorf D.
    • Lipson E.J.
    • et al.
    Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma.
    N Engl J Med. 2022; 386: 24-34
    View in Article

    • Google Scholar
42. • André T.
    • Shiu K.K.
    • Kim T.W.
    • et al.
    Pembrolizumab in microsatellite-instability-high advanced colorectal cancer.
    N Engl J Med. 2020; 383: 2207-2212
    View in Article

    • Google Scholar

43. Opdualag prescribing information. Opdualag U.S. Product information, 2022, Bristol-Myers Squibb Company; Princeton, NJ, Available at: https://news.bms.com/news/details/2022/U.S.-Food-and-Drug-Administration-Approves-First-LAG-3-Blocking-Antibody-Combination-Opdualag-nivolumab-and-relatlimab-rmbw-as-Treatment-for-Patients-with-Unresectable-or-Metastatic-Melanoma/default.aspx. Accessed September 16, 2022.

    View in Article

    • Google Scholar
44. • Sangro B.
    • Chan S.L.
    • Meyer T.
    • et al.
    Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.
    J Hepatol. 2020; 72: 320-341
    View in Article

    • Google Scholar
45. • Lanitis T.
    • Proskorovsky I.
    • Ambavane A.
    • et al.
    Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.
    Adv Ther. 2019; 36: 2327-2341
    View in Article

    • Google Scholar
46. • Wang P.F.
    • Chen Y.
    • Song S.Y.
    • et al.
    Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis.
    Front Pharmacol. 2017; 8: 730
    View in Article

    • Google Scholar
47. • Topalian S.L.
    • Sznol M.
    • McDermott D.F.
    • et al.
    Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
    J Clin Oncol. 2014; 32: 1020-1030
    View in Article

    • Google Scholar
48. • Ascierto P.A.
    • Del Vecchio M.
    • Robert C.
    • et al.
    Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
    Lancet Oncol. 2017; 18: 611-622
    View in Article

    • Google Scholar
49. • Croughan W.D.
    • Aranibar N.
    • Lee A.G.
    • et al.
    Understanding and Controlling Sialylation in a CHO Fc-Fusion Process.
    PLoS One. 2016; 11: e0157111
    View in Article

    • Google Scholar
50. • Wang D.Y.
    • Salem J.E.
    • Cohen J.V.
    • et al.
    Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    JAMA Oncol. 2018; 4: 1721-1728
    View in Article

    • Google Scholar
51. • Remash D.
    • Prince D.S.
    • McKenzie C.
    • et al.
    Immune checkpoint inhibitor-related hepatotoxicity: A review World.
    J Gastroenterol. 2021; 27: 5376-5391
    View in Article

    • Google Scholar
52. • Intlekofer A.M.
    • Thompson C.B.
    At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.
    J Leukoc Biol. 2013; 94: 25-39
    View in Article

    • Google Scholar
53. • Fujiwara Y.
    • Horita N.
    • Harrington M.
    • et al.
    Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials Cancer.
    Immunol Immunother. 2022; 71: 2837-2848
    View in Article

    • Google Scholar
54. • Wang W.
    • Lie P.
    • Guo M.
    • et al.
    Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data.
    Int J Cancer. 2017; 141: 1018-1028
    View in Article

    • Google Scholar
55. • Finn R.S.
    • Qin S.
    • Ikeda M.
    • et al.
    Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
    N Engl J Med. 2020; 382: 1894-1905
    View in Article

    • Google Scholar
56. • Finn R.S.
    • Ryoo B.Y.
    • Merle P.
    • et al.
    Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double- Blind, Phase III Trial.
    J Clin Oncol. 2020; 38: 193-202
    View in Article

    • Google Scholar
57. • Miah A.
    • Tinoco G.
    • Zhao Z.
    • et al.
    Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival.
    J Cancer Res Clin Oncol. 2022; https://doi.org/10.1007/s00432-022-04340-3
    View in Article

    • Google Scholar
58. • Pana J.
    • Liua L.
    • Guo X.
    • et al.
    Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Expert Opin Drug Saf. 2022; 21: 1275-1287
    View in Article

    • Google Scholar
59. • Björnsson E.
    • Stephens C.
    • Atallah E.
    • et al.
    A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry.
    Liver Int. 2022; 00: 1-12
    View in Article

    • Google Scholar

60. FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma, Available at: www.fda.gov/drugs/drug-approvals-anddatabases/fda-approves-atezolizumab-plus-bevacizumab-unresectablehepatocellular-carcinoma. Accessed June 1, 2020.

    View in Article

    • Google Scholar
61. • Naidoo J.
    • Page D.B.
    • Li B.T.
    • et al.
    Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
    Ann Oncol. 2015; 26: 2375-2391
    View in Article

    • Google Scholar
62. • Bessone F.
    • Bjornsson E.S.
    Checkpoint inhibitor-induced hepatotoxicity: role of liver biopsy and management approach.
    World J Hepatol. 2022; 14: 1269-1276
    View in Article

    • Google Scholar
63. • Weber J.S.
    • Kähler K.C.
    • Hauschild A.
    Management of immune-related adverse events and kinetics of response with ipilimumab.
    J Clin Oncol. 2012; 30: 2691-2697
    View in Article

    • Google Scholar
64. • De Martin E.
    • Michot J.M.
    • Papouin B.
    • et al.
    Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    J Hepatol. 2018; 68: 1181-1190
    View in Article

    • Google Scholar
65. • Huffman B.M.
    • Kottschade L.A.
    • Kamath P.S.
    • et al.
    Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management.
    Am J Clin Oncol. 2018; 41: 760-765
    View in Article

    • Google Scholar
66. • Kazuyuki M.
    • Takanori I.
    • Matsatoshi I.
    • et al.
    Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies.
    J Gastroenterol. 2020; 55: 653-661
    View in Article

    • Google Scholar
67. • Hamoir C.
    • de Vos M.
    • Clinckart F.
    • et al.
    Hepatobiliary AND PANCREATIC: NIVOLUMAB-RELATED CHolangiopathy.
    J Gastroenterol Hepatol. 2018; 33: 1695
    View in Article

    • Google Scholar
68. • Gudnason H.O.
    • Björnsson H.K.
    • Gardarsdottir M.
    • et al.
    Secondary sclerosing cholangitis in patients with drug-induced liver injury.
    Dig Liver Dis. 2015; 47: 502-507
    View in Article

    • Google Scholar
69. • Ahmad J.
    • Rossi S.
    • Rodgers S.K.
    • et al.
    Sclerosing cholangitis-like changes on magnetic resonance cholangiography in patients with drug induced liver injury.
    Clin Gastroenterol Hepatol. 2019; 17: 789-790
    View in Article

    • Google Scholar
70. • Cohen J.V.
    • Dougan M.
    • Zubiri L.
    • et al.
    Liver biopsy findings in patients on immune checkpoint inhibitors.
    Mod Pathol. 2021; 34: 426-437
    View in Article

    • Google Scholar
71. • Onoyama T.
    • Takeda Y.
    • Yamashita T.
    • et al.
    Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review.
    World J Gastroenterol. 2020; 26: 353-365
    View in Article

    • Google Scholar
72. • Li M.
    • Sack J.S.
    • Bell P.
    • et al.
    Utility of Liver Biopsy in Diagnosis and Management of High-grade Immune Checkpoint Inhibitor Hepatitis in Patients With Cancer.
    JAMA Oncol. 2021; 7: 1711-1714
    View in Article

    • Google Scholar
73. • Brahmer J.R.
    • Abu-Sbeih H.
    • Ascierto P.A.
    • et al.
    Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.
    J Immunother Cancer. 2021; 9: e002435
    View in Article

    • Google Scholar
74. • Haanen J.B.A.G.
    • Carbonnel F.
    • Robert C.
    • et al.
    Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2017; 28: iv119-iv142
    View in Article

    • Google Scholar

75. Management of immune-related adverse events (irAEs) | eviQ, Available at: https://www.eviq.org.au/clinical-resources/side-effect-and-toxicitymanagement/immunological/1993-management-of-immune-relatedadverse-events#collapse150419. Accessed March 4, 2022.

    View in Article

    • Google Scholar
76. • Brahmer J.R.
    • Lacchetti C.
    • Schneider B.J.
    • et al.
    Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
    J Clin Oncol. 2018; 36: 1714-1768
    View in Article

    • Google Scholar
77. • Peeraphatdit T.B.
    • Wang J.
    • Odenwald M.A.
    • et al.
    Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation.
    Hepatology. 2020; 72: 315-329
    View in Article

    • Google Scholar
78. • Miller E.D.
    • Abu-Sbeih H.
    • Styskel B.
    • et al.
    Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors.
    Am J Gastroenterol. 2020; 115: 251-261
    View in Article

    • Google Scholar
79. • Huffman B.M.
    • Kottschade L.A.
    • Kamath P.S.
    • et al.
    Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management.
    Am J Clin Oncol. 2018; 41: 760-765
    View in Article

    • Google Scholar
80. • Gauci M.L.
    • Baroudjian B.
    • Zeboulon C.
    • et al.
    Immune-related hepatitis with immunotherapy: are corticosteroids always needed?.
    J Hepatol. 2018; 69: 548-550
    View in Article

    • Google Scholar
81. • Riveiro-Barciela M.
    • Barreira-Díaz A.
    • Vidal-González J.
    • et al.
    Immune-related hepatitis related to checkpoint inhibitors: clinical and prognostic factors.
    Liver Int. 2020; 40: 1906-1916
    View in Article

    • Google Scholar
82. • Bhave P.
    • Buckle A.
    • Sandhu S.
    • et al.
    Mortality due to immunotherapy related hepatitis.
    J Hepatol. 2018; 69: 976-978
    View in Article

    • Google Scholar
83. • Fontana R.J.
    • Liou I.
    • Reuben A.
    • et al.
    AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury.
    Hepatology. 2022; https://doi.org/10.1002/hep.32689
    View in Article

    • Google Scholar
84. European Association for the Study of the Liver; Clinical Practice Guideline Panel: Chair; Panel members; EASL Governing Board representative. EASL Clinical Practice Guidelines: Drug-induced liver injury.
    J Hepatol. 2019; 70: 1222-1261
    View in Article

    • Google Scholar
85. • Ueno M.
    • Takabatake H.
    • Hata A.
    • et al.
    Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.
    Cancer Rep. 2022; 5: e1624
    View in Article

    • Google Scholar
86. • Doherty G.J.
    • Duckworth A.M.
    • Davies S.E.
    • et al.
    Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury.
    ESMO Open. 2017; 2: e000268
    View in Article

    • Google Scholar